Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.

Changes in the fibroblast growth factor receptor (FGFR) axis are often associated with prostate cancer (CaP) progression. We have used chemically induced dimerization (CID) to elucidate the individual contributions of FGFR1 and FGFR2 to tumor etiology. Novel CaP cell lines stably expressing CID/AP20187-inducible FGFR1 (iFGFR1) and iFGFR2 were made using the tumorigenic transgenic adenocarcinoma of the murine prostate (TRAMP)-derived clone, TRAMP-C2N (C2N), to generate C2N.iFGFR1 or C2N.iFGFR2 cells. To test the effects of iFGFR activation on tumor growth, mice bearing s.c. C2N.iFGFR1- or C2N.iFGFR2-derived tumors were treated biweekly with CID. Activation of iFGFR1 led to rapid tumor growth as a result of increased proliferation. In contrast, expression of iFGFR2 inhibited tumor growth. Furthermore, we have ascertained that FGFR1 activation appears to be most important during the early stages of tumor development, but once established, tumors become rapidly CID independent. In these C2N-based lines, quantitative signaling differences were seen between the two receptors, with iFGFR1 leading to more robust extracellular signal-regulated kinase activation. Additionally, activation of iFGFR1, but not iFGFR2, led to strong up-regulation of osteopontin, a secreted glycoprotein involved in integrin activation and associated with CaP progression and metastasis. These studies support the hypothesis that observed changes in the FGFR axis in mammals during CaP progression are causally important.

[1]  A. Harris,et al.  Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. , 2001, Anticancer research.

[2]  K. Pienta,et al.  The Role of αvβ3 in Prostate Cancer Progression , 2002 .

[3]  K. Pienta,et al.  The Role of v3 in Prostate Cancer Progression 1 , 2002 .

[4]  N. Bouck,et al.  Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate , 2001, The Prostate.

[5]  U. Studer,et al.  Osteopontin: possible role in prostate cancer progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  J. Simons,et al.  Angiogenesis and prostate cancer: identification of a molecular progression switch. , 2001, Cancer research.

[7]  B. Berse,et al.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. , 1994, Oncogene.

[8]  A. Vercoutter-Edouart,et al.  FGF signals for cell proliferation and migration through different pathways. , 2000, Cytokine & growth factor reviews.

[9]  K. Peterson,et al.  A proliferation switch for genetically modified cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Oparil,et al.  Fibroblast Growth Factor Receptor-1 Signaling Induces Osteopontin Expression and Vascular Smooth Muscle Cell–Dependent Adventitial Fibroblast Migration In Vitro , 2002, Circulation.

[11]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[12]  A. Matsubara,et al.  Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. , 1998, Cancer research.

[13]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[14]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Matsubara,et al.  Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. , 1997, Cancer research.

[16]  T. Khan,et al.  Improved artificial death switches based on caspases and FADD. , 1999, Human gene therapy.

[17]  S. Philip,et al.  Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[18]  C. Powers,et al.  Fibroblast growth factors, their receptors and signaling. , 2000, Endocrine-related cancer.

[19]  Shannon R. Magari,et al.  Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Thompson,et al.  Comparison of the intracellular signaling responses by three chimeric fibroblast growth factor receptors in PC12 cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Kan,et al.  Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  O. Cussenot,et al.  Down‐regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate , 2002, The Prostate.

[23]  S. Schreiber,et al.  A general strategy for producing conditional alleles of Src-like tyrosine kinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Ittmann,et al.  Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. , 2001, Journal of the National Cancer Institute.

[25]  M. Ittmann,et al.  Alternative splicing of fibroblast growth factor receptors in human prostate cancer , 2001, The Prostate.

[26]  N. Greenberg,et al.  A Transgenic Mouse Prostate Cancer Model , 1996, Toxicologic pathology.

[27]  B. Foster,et al.  Peptide Growth Factors and Prostate Cancer: New Models, New Opportunities , 1998, Cancer and Metastasis Reviews.

[28]  D. Spencer,et al.  Synthetic activation of caspases: artificial death switches. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  B. Foster,et al.  Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. , 1997, Cancer research.

[30]  A. Angelucci,et al.  Osteopontin Modulates Prostate Carcinoma Invasive Capacity through RGD-Dependent Upregulation of Plasminogen Activators , 2002, Biological chemistry.

[31]  Z. Hall.  Cancer , 1906, The Hospital.

[32]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  M. Nevalainen,et al.  Increased Expression of FGF-8 Isoforms and FGF Receptors in Human Premalignant Prostatic Intraepithelial Neoplasia Lesions and Prostate Cancer , 2001, Laboratory Investigation.

[34]  B. Foster,et al.  Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[35]  Russ P Carstens,et al.  Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer , 1997, Oncogene.